Hepion pharmaceuticals strengthens board of directors with appointment of michael purcell

Edison, n.j., march 06, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, and other chronic diseases, today announced the appointment of michael purcell to the company's board of directors, effective march 5, 2024.
HEPA Ratings Summary
HEPA Quant Ranking